Table 2.
No. | Drug | Application | Target | Mechanism | Ref. |
---|---|---|---|---|---|
1 | MtZFNs | Zebra fishes Hek 293T cells |
mtDNA | Bind and cleave the mutated DNA and retains the wild type mtDNA | 31 |
2 | Mito TALENs | iPSC cells | mtDNA | Deletion sites for selective cleavage of mtDNA | 32 |
3 | Mito CRISPR/Cas9 | HEK-292T cells | mtDNA | Mitochondrial specific CAS 9 editing mtDNA m.3243A>G gene sites or knock in homologous recombination strategy to repair mutated mtDNA | 33,34 |
4 | DdCBE | HEK293T cells | mtDNA | Specifically catalyzes the transformation of CG base pairs of mtDNA into AT | 35 |
5 | Mito-Porter | Hela cells G625A cells |
mtRNA | Knockdown the mRNA encoded complex Ⅱ or introduce mito codon regulation system | 27 |
6 | ZFNs | iPSC cells | SNCA gene | Reprogram A53T mutation in iPSCs | 36 |
7 | TALENs | iPSC cells | CAG gene | Replace pathogenic CAG repeats with normal repeats gene sequences through homologous recombination | 37 |
8 | CRISPR/KamiCas9 | HD mice model | hHTT-82Q gene | sgHTT1 targeting HTT gene with the aim of permanently blocking leading to HTT silencing | 38 |
9 | Bip-V5 | Rat 6-OHDA PD model | BAX/BAK | Inhibit BCL-2 | 39 |
10 | MANF | Rat 6-OHDA PD model | BAX | Inhibit BAX activation | 40 |
11 | KuA | Mice MPP+ model | BAX/BCL-2 | Reduce BAX/BCL-2 ratio | 41 |
12 | VBIT-3, VBIT-4 | MEF cells | VDAC1 | Inhibition of VDAC1 oligomerization | 42 |
13 | VDAC1 N-terminal peptides | NSC-34 cells | VDAC1 | Interact with VDAC1, reduce channel conductance | 43 |
14 | Nobiletin | Rat model | Complex Ⅰ | Restored the activity of complex Ⅰ | 44 |
15 | NaHS | Animal model | ETC | Mediated oxygen consumption rate | 45 |
16 | Compound A | Rat PD model | Complex Ⅱ | Blocked BIM-induced apoptosis after BAX is activated on the mitochondria | 46 |
17 | rT1 | COS-7 cells | ATP synthase | Through TOM20 targets mitochondrial membrane ATP synthase | 47 |
18 | Nicotinamide riboside/NR | A-T fibroblasts, Atm–/– mice | NAD+ | Boosted NAD+ levels by promoting mitophagy in a PINK1-dependent manner | 48 |
19 | Rapamycin | SCIRI mice model | mTOR | Promoted mitophagy and attenuating SCIRI-induced apoptosis | 49 |
20 | Urolithin A | C. elegans AD models | PINK1 | Stimulated mitophagy, suppressed of neuroinflammation | 50 |
21 | Rilmenidine | ALS mice | SOD1 | Induced autophagy, promoted autophagic clearance of mutant SOD1 and efficient mitophagy | 51 |
22 | Mito Q | Rat LTP model | ROS | Mitochondria-targeted antioxidants | 52 |
23 | Mito-TEMPO | Primary microglia | ROS | Inhibit the increase of TNF-α, IL-1β, IL-6 and iNOS | 53 |
24 | SS peptides | Caco2 cells | ROS | Targeted delivery of antioxidants to the inner mitochondrial membrane | 54 |
25 | Pyridoxine | PC12 cells | GSH | Alleviated the significant decrease of GSH to maintain the activity of complex Ⅰ | 55 |